Residual disease is a strong prognostic marker in patients with acute lymphoblastic leukaemia with chemotherapy‐refractory or relapsed disease prior to allogeneic stem cell transplantation-Reference-Cited by-同舟云学术

Residual disease is a strong prognostic marker in patients with acute lymphoblastic leukaemia with chemotherapy‐refractory or relapsed disease prior to allogeneic stem cell transplantation

Published:2021-06-22 Issue:2 Volume:194 Page:403-413
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br. J. Haematol.

Author:

Nakamura Momoko¹,Arai Yasuyuki¹²^ORCID,Hirabayashi Shigeki¹,Kondo Tadakazu¹^ORCID,Doki Noriko³^ORCID,Uchida Naoyuki⁴,Fukuda Takahiro⁵,Ozawa Yukiyasu⁶,Tanaka Masatsugu⁷,Sawa Masashi⁸,Katayama Yuta⁹,Kanda Yoshinobu¹⁰,Shiratori Souichi¹¹^ORCID,Nakamae Hirohisa¹²^ORCID,Yoshioka Satoshi¹³,Onizuka Makoto¹⁴,Ichinohe Tatsuo¹⁵,Atsuta Yoshiko¹⁶¹⁷^ORCID,Kako Shinichi¹⁰^ORCID

Affiliation:

1. Department of Hematology and Oncology Graduate School of Medicine, Kyoto University KyotoJapan

2. Department of Clinical Laboratory Medicine Graduate School of Medicine, Kyoto University KyotoJapan

3. Hematology Division Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital TokyoJapan

4. Department of Hematology Federation of National Public Service Personnel Mutual Aid Associations Toranomon Hospital TokyoJapan

5. Department of Hematopoietic Stem Cell Transplantation National Cancer Center Hospital TokyoJapan

6. Department of Hematology Japanese Red Cross Nagoya First Hospital AichiJapan

7. Department of Hematology Kanagawa Cancer Center KanagawaJapan

8. Department of Hematology and Oncology Anjo Kosei Hospital AichiJapan

9. Department of Hematology Hiroshima Red Cross Hospital & Atomic‐bomb Survivors Hospital HiroshimaJapan

10. Division of Hematology Jichi Medical University Saitama Medical Center SaitamaJapan

11. Department of Hematology Hokkaido University Hospital HokkaidoJapan

12. Graduate School of Medicine Osaka City University OsakaJapan

13. Department of Hematology Kobe City Medical Center General Hospital HyogoJapan

14. Department of Hematology/Oncology Tokai University School of Medicine KanagawaJapan

15. Department of Hematology and Oncology Research Institute for Radiation Biology and Medicine, Hiroshima University HiroshimaJapan

16. Japanese Data Center for Hematopoietic Cell Transplantation AichiJapan

17. Department of Healthcare Administration Nagoya University Graduate School of Medicine Aichi Japan

Funder

Foundation for Promotion of Cancer Research

Pfizer

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.17646

Reference30 articles.

1. Adult Acute Lymphoblastic Leukemia

2. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia

3. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study

4. At three years, patients with acute lymphoblastic leukaemia are still at risk for relapse. Results of the international MRC UKALLXII/ECOG E2993 trial

5. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The road more or less traveled- Examining the role of consolidative allogeneic hematopoietic stem cell transplantation after chimeric antigen receptor T cell therapy in B-cell ALL;Seminars in Hematology;2024-08

2. Advantages of peripheral blood stem cells from unrelated donors versus bone marrow transplants in outcomes of adult acute myeloid leukemia patients;Cytotherapy;2022-10

3. Overcoming minimal residual disease using intensified conditioning with medium-dose etoposide, cyclophosphamide and total body irradiation in allogeneic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults;Cytotherapy;2022-09

4. Post-transplant GVHD in the era of molecularly targeted therapy;Japanese Journal of Transplantation and Cellular Therapy;2022